March 9 Quick Takes: A first for Boehringer’s Ofev; plus Cel-Sci’s COVID-19 therapy, Sinopharm, AZ, Urovant, Hengrui, Trevena, and Tetra-Shionogi

Boehringer’s Ofev approved as first therapy for lung scarring disease
FDA approved Ofev nintedanib from Boehringer Ingelheim GmbH as the first therapy for chronic fibrosing interstitial lung diseases; the NDA had received Priority Review. The small molecule inhibitor of VEGF, PDGFR and FGFR is already approved to treat idiopathic pulmonary fibrosis and systemic sclerosis interstitial lung disease.

Cel-Sci developing peptide-based COVID-19 therapy
Cel-Sci Corp. (NYSE-A:CVM) is

Read the full 638 word article

How to gain access

Continue reading with a
two-week free trial.